Figure 2
Figure 2. FeCl3 carotid artery studies. Transgenic lines for pIR8 (A) and pcBF8 (B) were studied for clot development in the carotid artery injured with 20%, 15% and 10% FeCl3 for 2 minutes (left to right). Mean ± 1 SD of blood flow rate seen over 30 minutes are shown for the various transgenic lines (defined on the right) represented at their mean pF8 antigenic levels in Figure 1A and B. Gray horizontal bars indicate the mean ± SD for blood flow rate in WT (bottom bar) and F8null (top bar) mice. N-5 mice per arm. *P < .035 relative to phF8.38. Panels C and D show BMT/lentiviral F8null studies for average blood flow (C) and the average time to occlusion (D) over 30 minutes. Gray horizontal bars indicate the mean ± SD for time to occlusion in WT (bottom bar) and F8null (top bar) mice. N < 8 mice per arm. ** P < .02 and ***P < .002 for ubiquitin and PF4 promoter-driven vector mice relative to F8null mice.

FeCl3 carotid artery studies. Transgenic lines for pIR8 (A) and pcBF8 (B) were studied for clot development in the carotid artery injured with 20%, 15% and 10% FeCl3 for 2 minutes (left to right). Mean ± 1 SD of blood flow rate seen over 30 minutes are shown for the various transgenic lines (defined on the right) represented at their mean pF8 antigenic levels in Figure 1A and B. Gray horizontal bars indicate the mean ± SD for blood flow rate in WT (bottom bar) and F8null (top bar) mice. N-5 mice per arm. *P < .035 relative to phF8.38. Panels C and D show BMT/lentiviral F8null studies for average blood flow (C) and the average time to occlusion (D) over 30 minutes. Gray horizontal bars indicate the mean ± SD for time to occlusion in WT (bottom bar) and F8null (top bar) mice. N < 8 mice per arm. ** P < .02 and ***P < .002 for ubiquitin and PF4 promoter-driven vector mice relative to F8null mice.

Close Modal

or Create an Account

Close Modal
Close Modal